Numis Securities downgraded shares of Hikma Pharmaceuticals (LON:HIK) to an add rating in a research report released on Friday morning. Numis Securities currently has GBX 1,560 ($21.16) price objective on the stock, up from their prior price objective of GBX 1,300 ($17.63).
Several other equities analysts also recently issued reports on HIK. Jefferies Group reaffirmed a hold rating and set a GBX 997 ($13.52) price objective on shares of Hikma Pharmaceuticals in a report on Friday. Peel Hunt reaffirmed a hold rating on shares of Hikma Pharmaceuticals in a report on Friday. JPMorgan Chase increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,000 ($13.56) to GBX 1,050 ($14.24) and gave the company a neutral rating in a report on Thursday, March 15th. Morgan Stanley increased their target price on shares of Hikma Pharmaceuticals from GBX 1,000 ($13.56) to GBX 1,050 ($14.24) and gave the company an equal weight rating in a research report on Thursday, March 15th. Finally, Citigroup upgraded shares of Hikma Pharmaceuticals to a buy rating and set a GBX 1,250 ($16.96) target price for the company in a research report on Thursday, March 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of GBX 1,131.70 ($15.35).
Hikma Pharmaceuticals traded up GBX 13.50 ($0.18), hitting GBX 1,413.50 ($19.17), during midday trading on Friday, according to Marketbeat Ratings. 884,945 shares of the company traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 52-week low of GBX 814.20 ($11.04) and a 52-week high of GBX 2,346 ($31.82).
The firm also recently announced a dividend, which will be paid on Thursday, May 24th. Stockholders of record on Thursday, April 5th will be given a $0.23 dividend. This represents a dividend yield of 1.47%. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.22. The ex-dividend date is Thursday, April 5th.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.